"By Donald Zuhn --
Logo_sbm SinoBiomed announced today that the U.S. Patent & Trademark Office has issued U.S. Patent No. 7,101,556, which is directed to fusion proteins comprising the Plasmodium merozoite surface protein-1 (MSP1) and the Plasmodium apical membrane antigen 1 (AMA-1) and the production of anti-malarial vaccines using such proteins. In its release, SinoBiomed states that the '556 patent covers the malaria vaccine PfCP2.9, the exclusive rights to which SinoBiomed acquired through its subsidiary, Shanghai Wanxing Bio-pharmaceuticals Co. Ltd. Shanghai Wanxing Bio-pharmaceuticals had previously acquired the rights to the '556 patent from assignee Second Military Medical University."
